ABSTRACT

Objective: The goal of this research was to evaluate the individual cardio-protective properties of Lignagliptin and Empagliflozin as well as their combination effects on a rat experimental model of cardiotoxicity. Materials and Methods: Out of the animals, five groups of six each were formed. For 15 days, Group I was given the medium (0.5% carboxy methyl cellulose) and functioned as the standard control group. On days 14 and 15, Isoproterenol (85 mg/kg, s.c.) was given to Group II, which acted as the disease control group. As a drug-treated group, Group III received Isoproterenol (85mg/kg, s.c.) on the 14th and 15th days as well as Empagliflozin (10 mg/kg/day, p.o.) for 15 days. Linagliptin (5 mg/kg/day, p.o.) for 15 days and isoproterenol on the 14th and 15th days were administered to Group IV as part of their drug treatment regimen. Group V served as the drug- treated group and got isoproterenol (85 mg/kg, s.c.) on the 14th and 15th days along with a 15-day combination of Empagliflozin (10 mg/kg) and linagliptin (5 mg/kg) administered orally. Result: At the end of the treatment period, animals were anaesthetized with an aesthetic ether after final drugs dose administration and then blood was collected from the retro-orbital plexus for estimation of different biochemical parameters like blood glucose (BG), creatine kinase MB (CK- MB), lactate dehydrogenase (LDH), Aspartate amino transferase, High sensitivity C reactive protein (HSCRP), lipid profile, animals were euthanized and hearts were isolated for Histopathological examination. Conclusion: The results showed that Empagliflozin and Linagliptin together had better cardio protective benefits along with positive impacts on cardiotoxicity. Keywords: Cardiotoxicity, Empagliflozin, Linagliptin, Isoproterenol
Publication date: 15/10/2023

https://ijbpas.com/pdf/2023/October/MS_IJBPAS_2023_OCTOBER_SPCL_1002.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.10.1002